Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Status:
Completed
Trial end date:
2021-01-28
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety and efficacy of Losmapimod in treating patients with
Facioscapulohumeral Muscular Dystrophy (FSHD) over 48 weeks.